Optimal glycemic control with minimal hypo- and hyperglycemia in type 1 diabetes (T1D) is difficult to achieve. New technologies such as hybrid closed loop (HCL-670G) system could help to improve glycemic control and prevent complications. We report a single-center 6-month experience regarding changes in metrics for glycemic control in adult patients with T1D on the Medtronic® 670G system. There were 139 patients (mean±SD age 41±12 years, 60% women) with T1D who were on a pump and CGM for at least 3 months prior to initiating 670G system, and who had at least six months of follow-up on 670G. We analyzed the changes in HbA1c, daily insulin dose, and BMI from baseline (just prior to initiating 670G system) at 3 and 6-months of 670G use. The mean percent time in auto-mode was 71% at 3 months and 73% at 6 months, with a range of 0-99% at both time points. Use of the 670G system significantly improved HbA1c with no change in BMI (Table). Percent time in auto-mode was significantly correlated to HbA1c at 3 (r=-0.26, p=0.009) and 6 months (r=-0.32, p=0.002). Daily bolus and total insulin dose increased at 3 months but were not significantly higher than pre-670G after 6 months of 670G use. We conclude that HCL use in real-life improves glucose control without increasing body weight or insulin dose.
D.A. Giordano: None. J.K. Snell-Bergeon: None. H. Joseph: None. S.K. Garg: Advisory Panel; Self; Eli Lilly and Company, Roche Pharma, Sanofi-Aventis, Zealand Pharma A/S. Research Support; Self; Eli Lilly and Company, WebMD. H.K. Akturk: Advisory Panel; Self; Sanofi. Research Support; Self; Eli Lilly and Company, MannKind Corporation, REMD Biotherapeutics. Speaker's Bureau; Self; MannKind Corporation.